Levent Karabas, Hande Etus*, Bengu Yucel, Yusuf Çaglar (Kocaeli, Turkey)

Advantages:

To evaluate safety and efficacy of photodynamic therapy (PDT) with Verteporfin combined with intravitreal bevacizumab for choroidal neovascularization associated with angioid streaks.

Methods:

Six eyes of six patients treated with PDT with Verteporfin and 0, 05 mg/ml Bevacizumab injections were included. Standardized protocol, visual acuity (VA), ophthalmologic examinations, optic coherence tomography and fluorescein angiograms were used to evaluate the results.

Effectiveness / Safety:

The mean age was 46.8 (33-56). The mean follow-up was 27.5 months (range10 to 35 months). The mean preoperative VA was 0.23 (range, 0.01 to 0.7) and 0.46 (range, 0.1 to 1.0) at the final visit .The VA improved at the final visit in 5 eyes (84 %), and decreased in 1 eyes (16 %). The final fluorescein angiography examination that showed no leakage, minimal leakage, and persistent or recurrent leakage, recurrence after the last Bevacizumab injection were examined. New CNV lesions developed in no eyes. PDT or Bevacizumab injections related complications were not reported in any case.

Take home message:

PDT with Verteporfin combined with Bevacizumab injections seems to maintain visual acuity. Further studies with big number of cases are required to validate these findings.